Scale -


  • Revenue is 33653 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • Ebitda is 7338 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 12 %
  • Quarterly Revenue is 9106 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile
  • Quarterly Profit is 1034 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile
  • PBT is 1517 Rs Cr; in Top Quartile; 5 Year CAGR is 11 %

Profitability -


  • PBDIT Margin is 21.8 %; in Bottom Quartile
  • PAT Margin is 10.4 %; in Bottom Quartile
  • Quarterly Profit margin is 11 %; in Bottom Quartile

Return -


  • ROA is 5.99 %; Continuous Decline over 3 years; in Bottom Quartile
  • Asset Turnover is 62 %; Continuous Decline over 3 years
  • ROCE is 13.73 %; in Bottom Quartile
  • ROE is 9.24 %; in Bottom Quartile

Efficiency -


  • Operating cash flow is 5526 Rs Cr; Annual Growth is 41 %; Continuous Growth over 3 years; in Top Quartile
  • Inventory Turnover Ratio is 2.98; 5 Year CAGR is 35 %; in Bottom Quartile
  • Current Ratio is 1.81; Continuous Decline over 3 years

Solvancy -


  • Long term Debt is 803 Rs Cr; Annual Decline is -49 %; Continuous Decline over 3 years; in Top Quartile; 5 Year CAGR is 34 %
  • Total Debt is 7676 Rs Cr; in Top Quartile; 5 Year CAGR is 34 %
  • Contingent Liabilities is 3636 Rs Cr; in Top Quartile; 5 Year CAGR is 33 %

Quality -


  • Operating cashflow/ebitda is 75 %; Annual Growth is 38 %; Continuous Growth over 3 years; in Top Quartile
  • Operating cashflow/PAT is 158 %; Annual Growth is 41 %; Continuous Growth over 3 years; in Top Quartile
  • Change in Inventories/Total Expenses is -1 %; Annual Growth is 54 %; Continuous Growth over 3 years
  • Other Expenses/Total Expenses is 28 %; Continuous Growth over 3 years
  • Current Tax/PAT is 50 %; in Top Quartile; 5 Year CAGR is 19 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Aurobindo Pharma (NSE:AUROPHARMA) Announces Q2FY27 Earnings Call Date and Details
Aurobindo Pharma Q2FY27 Earnings Call Set for 5 Nov 2026
What Aurobindo Pharma Shareholders Got Right
Aurobindo Pharma Ltd Estimates – NSE:AUROPHARMA
Sona BLW, Solar Industries, Oracle, Aurobindo Pharma, CG Power: Midcap performers of 2026, price targets and more
Aurobindo Pharma's Apitoria Acquires 80% Stake in A1 Biochem Labs India
Aurobindo arm Apitoria completes $15.25 million acquisition of A1 Biochem Labs
Aurobindo Pharma completes A1 Biochem CRO acquisition to build integrated CRDMO platform
Aurobindo subsidiary completes US CRDMO acquisition for $15.247 million
Aurobindo Arm Acrotech Launches ADQUEY in US for Atopic Dermatitis, Enters Dermatology Market
Aurobindo Pharma launches Adquey in US; Nuvama sees $300 million peak sales
Aurobindo Pharma Launches Adquey Ointment in US